MIT Engineers Create Injectable Mini Livers to Replace Organ Transplants

Revolutionary Treatment Could Save Thousands of Lives

For the more than 10,000 Americans waiting for liver transplants, hope may come in the form of a simple injection. More than 10,000 Americans who suffer from chronic liver disease are on a waitlist for a liver transplant, but there are not enough donated organs for all of those patients. Additionally, many people with liver failure aren't eligible for a transplant if they are not healthy enough to tolerate the surgery.

MIT researchers have developed what they call "satellite livers" — injectable mixtures of liver cells that can temporarily take over for failing organs. "We think of these as satellite livers," explains Sangeeta Bhatia, the lead researcher. "If we could deliver these cells into the body while leaving the sick organ in place, that would provide booster function." The breakthrough could revolutionize treatment for liver disease and extend how long patients can survive while waiting for donor organs.

The technology works by combining liver cells called hepatocytes with specially engineered hydrogel microspheres. These spheres have special properties that allow them to act like a liquid when they are closely packed together, so they can be injected through a syringe and then regain their solid structure once inside the body. The injected mixture also includes fibroblast cells—supportive cells that help the hepatocytes survive and promote the growth of blood vessels into the tissue.

How the Science Works

The key innovation lies in creating an environment where transplanted liver cells can survive and function. "What we did is use this technology to create an engineered niche for cell transplantation," Kumar told the publication. "If the cells are injected in the absence of these spheres, they would not integrate efficiently with the host, but these microspheres provide the hepatocytes with a niche where they can stay localized and become connected to the host circulation much faster."

Working with Nicole Henning, an ultrasound research specialist at the Koch Institute, the researchers developed a way to inject the cell mixture using a syringe guided by ultrasound. The procedure is minimally invasive — researchers inject the mixture into fatty tissue, such as the abdomen. "For a vast majority of liver disorders, the graft does not need to sit close to the liver," Kumar says.

Once injected, something remarkable happens. Over time, blood vessels begin to grow into the graft area, helping the injected hepatocytes to stay healthy. "The new blood vessels formed right next to the hepatocytes, which is why they were able to survive," Kumar says. "They were able to get the nutrients delivered right to them, they were able to function the way they're supposed to, and they produced the proteins that we expect them to."

Promising Test Results

In mouse studies, the results exceeded expectations. After injection, the cells remained viable and able to secrete specialized proteins into the host circulation for eight weeks, the length of the study. The human liver plays a role in about 500 essential functions, including regulation of blood clotting, removing bacteria from the bloodstream, and metabolizing drugs. The satellite livers demonstrated they could perform many of these critical tasks.

The treatment offers flexibility that traditional transplants cannot. In the future, similar grafts could be delivered to other sites in the body, such as into the spleen or near the kidneys. As long as they have enough space and access to blood vessels, the injected hepatocytes can function similarly to hepatocytes in the liver.

The Path Forward

That suggests that the therapy could potentially work as a long-term treatment for liver disease, the researchers say. While human trials are still needed, the technology represents a fundamental shift in how we might treat organ failure. "Injectable, self-assembling niches represent a significant step toward regenerative treatments that are more scalable and accessible to patients who may not receive a donor organ," the researchers explained.

The implications extend beyond liver disease. The implications of this research extend beyond liver diseases, as the conceptual framework of injectable, self-assembling cellular niches presents a prototype for regenerative therapies applicable to other organs and tissues. The successful harmonization of biomaterials engineering, cell biology, and medical imaging heralds a new era where minimally invasive, precision-guided cellular therapies can address organ failure more safely, efficiently, and accessibly.